Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial.

Isao Hara Shimpei Yamashita Satoshi Nishizawa Kazuro Kikkawa Toshio Shimokawa Yasuo Kohjimoto

Published in: JMIR research protocols (2018)

University Hospital Medical Information Network UMIN000022102; https://upload.umin.ac.jp /cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025463 (Archived by WebCite at http://www.webcitation.org/70xaQfGlJ).

Keyphrases

double blind
prostate cancer
placebo controlled
open label
minimally invasive
phase iii
healthcare
clinical trial
randomized controlled trial
phase ii
cross sectional
social media